Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study
Authors' conclusion
In US clinical practice, adding GLP-1RA to empagliflozin was associated with lower risks of MACE and HHF-mortality compared with adding DPP-4i. Among GLP-1RA initiators, adding empagliflozin was associated with lower cardiovascular risk than adding sulfonylureas
Study context
- Population
- Adults with T2D in routine care, US healthcare databases (2013–2022)
- Exposure
- Empagliflozin + GLP-1RA vs empagliflozin + DPP-4i; GLP-1RA + empagliflozin vs GLP-1RA + sulfonylurea
- Outcome
- Modified major adverse cardiovascular events (MACE) (MI, stroke, all-cause mortality) and composite of hospitalization for heart failure (HHF) or all-cause mortality
Methodological detailspropensity score matching weights, adjusted for over 130 baseline covariates, US healthcare databases (Medicare, Optum Clinformatics, MarketScan)
- Propensity score matching weights
- Adjusted for over 130 baseline covariates
- US healthcare databases (Medicare, Optum Clinformatics, MarketScan)
Main finding
As reported in the abstract
Estimate (95% CI)
Empagliflozin-GLP-1RAvs Empagliflozin-DPP-4i
HR (MACE) 0.81(0.67–0.97)
Empagliflozin-GLP-1RAvs Empagliflozin-DPP-4i
HR (HHF-mortality) 0.61(0.48–0.77)
GLP-1RA-empagliflozinvs GLP-1RA-sulfonylurea
HR (MACE) 0.68(0.56–0.81)
GLP-1RA-empagliflozinvs GLP-1RA-sulfonylurea
HR (HHF-mortality) 0.62(0.51–0.76)
Estimate (95% CI)
Empagliflozin-GLP-1RAvs Empagliflozin-DPP-4i
RD (MACE) −3.7 per 1,000 person-years(−7.1 to −0.2)
Empagliflozin-GLP-1RAvs Empagliflozin-DPP-4i
RD (HHF-mortality) −6.6 per 1,000 person-years(−9.3 to −3.9)
GLP-1RA-empagliflozinvs GLP-1RA-sulfonylurea
RD (MACE) −5.3 per 1,000 person-years(−7.9 to −2.6)
GLP-1RA-empagliflozinvs GLP-1RA-sulfonylurea
RD (HHF-mortality) −3.7 per 1,000 person-years(−6.1 to −1.8)
Observational data: associations, not effects.
Original publication
Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study. Cardiovasc Diabetol. Published 12 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →